Repligen | RGEN - Current Assets


Repligen reported $1.14B in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Agilent USD 4.62B 21M Dec/2025
Align Technology USD 2.62B 82.47M Dec/2025
Bio Techne USD 637.43M 27.92M Dec/2025
BioMarin Pharmaceutical USD 3.95B 98.95M Dec/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Bruker USD 2.21B 138.1M Dec/2025
Charles River Laboratories USD 1.45B 85.06M Dec/2025
Danaher USD 12.76B 3.15B Dec/2025
Dentsply International USD 2.02B 49M Dec/2025
General Electric Aerospace USD 40.6B 522M Dec/2025
Henry Schein USD 4.46B 69M Dec/2025
Illumina USD 3.29B 493M Dec/2025
IQVIA Holdings USD 6.25B 270M Dec/2025
Mettler Toledo International USD 1.36B 81.46M Dec/2025
Myriad Genetics USD 332.6M 12.2M Dec/2025
OraSure Technologies USD 261.91M 21.1M Dec/2025
Pacific Biosciences Of California USD 375.05M 19.18M Dec/2025
Pfizer USD 46.92B 3.22B Sep/2025
Repligen USD 1.14B 40.9M Dec/2025
Revvity USD 2.24B 95.96M Dec/2025
Standard Biotools USD 454.26M 18.18M Dec/2025
Thermo Fisher Scientific USD 28.71B 6.41B Dec/2025
Waters USD 1.99B 69.86M Dec/2025
West Pharmaceutical Services USD 1.98B 154.9M Dec/2025